Literature DB >> 31627930

[Tattoo hypersensitivity reaction in a patient receiving combined BRAF and MEK inhibitors].

E Rohmer1, J-N Scrivener2, C Schissler2, B Cribier2, C Lenormand2.   

Abstract

INTRODUCTION: For inflammation of a tattoo occurring decades after its creation, sarcoidosis should be considered first of all. Two case of extremely delayed hypersensitivity tattoo reaction have been recently reported in patients treated with BRAF and MEK inhibitors. We report a similar new case strongly suggesting a specific effect of this drug combination. PATIENTS AND METHODS: A 58-year-old man bearing 20-year-old tattoos was treated with dabrafenib and trametinib for advanced melanoma. A painful erythematous swelling appeared on all the patient's tattoos two months later, while his general tolerance of the treatment was poor. Skin biopsy demonstrated perivascular lympho-histiocytic infiltrate without granuloma, but with prominent pigment-loaded macrophages. Inflammatory signs quickly regressed after drug discontinuation. DISCUSSION: Great similarity exists between this new case and the first reported case, in which a female patient presented painful infiltration of old tattoos following repeated reintroduction of dabrafenib and trametinib in a setting of advanced melanoma. The immunomodulatory properties BRAF/MEK inhibition may enhance loss of tolerance to tattoo ink, accounting for the extremely long time to reaction. This third case militates in favour of a specific drug-induced reaction, of which patients with tattoos should be informed when anti-BRAF/MEK therapy is being considered.
Copyright © 2019 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  BRAF inhibitor; Hypersensibilité retardée; Hypersensitivity reaction; MEK inhibitor; Metastatic melanoma; Mélanome métastatique; Tatouage; Tattoos; Thérapie ciblée anti-BRAF; Thérapie ciblée anti-MEK

Mesh:

Substances:

Year:  2019        PMID: 31627930     DOI: 10.1016/j.annder.2019.08.012

Source DB:  PubMed          Journal:  Ann Dermatol Venereol        ISSN: 0151-9638            Impact factor:   0.777


  1 in total

1.  Case Report: Immune-Related Toxicity During Adjuvant Treatment With BRAF Plus MEK Inhibitors in a Melanoma Patient.

Authors:  Andrea Boutros; Chiara Schiavi; Federica Cecchi; Francesco Spagnolo; Antonio Guadagno; Enrica Teresa Tanda; Francesca Giusti; Giuseppe Murdaca; Paola Queirolo
Journal:  Front Immunol       Date:  2020-11-17       Impact factor: 7.561

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.